Bipartisan Bill to Limit US Biotech Deals with China Remains in Limbo

A bipartisan bill introduced in the House seeks to bar U.S. biotechnology firms from entering into collaborations or licensing agreements with Chinese companies.

The proposal sparked strong reactions across the industry last month, with many companies warning of potential disruptions to research partnerships and supply chains.

As of now the legislation is stalled, with no clear timetable for a vote, leaving the sector uncertain about future compliance requirements.